Ebselen oxide, formed by the oxidation of ebselen, is a novel and potent inhibitor of Histone deacetylase (HDAC1/3/4/5/6/7/8/9).
LY83583 (LY 83583; LY-83583) is a novel and potent inhibitor of multple target proteins such as Msp1 and guanylate cyclase, also acts as a cGMP modulator that inhibits cGMP production. Reference: Naunyn-Schmiedeberg’s archives of pharmacology, 1989, 340(1): 119-125.
Cinaciguat (formerly also known as BAY582667 or BAY58-2667) is a novel and potent activator of soluble guanylate cyclase (sGC) used for acute decompensated heart failure.
Plecanatide acetate, the acetate salt of plecanatide, is a guanylate cyclase-C (GC-C) receptor agonist with anti-inflammatory activity. It activates GCC with an EC50 of 190 nM in T84 cells. Plecanatide acetate shows anti-inflammatory activity in models of murine colitis. Plecanatide (Trulance; SP304; SP-304) is a drug approved by FDA for the treatment of chronic idiopathic […]
Riociguat (formerly also known as BAY-63-2521, BAY-632521; trade name Adempas) is a first-in-class and oral bioavailable soluble guanylate cyclase (GC) stimulator that has been approved to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).
Lificiguat, formerly known as YC-1, is a potent inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha).
Cinaciguat HCl, the hydrochloride salt of Cinaciguat (formerly also known as BAY582667 or BAY58-2667), is a novel and potent activator of soluble guanylate cyclase (sGC) used for acute decompensated heart failure.
BAY 41-2272 is a novel and potent activator of nitric oxide-sensitive guanylyl cyclase (NO-sensitive GC) with EC50 values of 0.3 μmol/L and 3 μmol/L in the presence and absence of 100 nmol/L DEA-NO, respectively.
Nelociguat (also known as BAY60-4552) is a nitric oxide sensitive soluble guanylate cyclase stimulator (sGC stimulator).
ODQ is a novel, potent and selective inhibitor of soluble guanylyl cyclase (sGC). The binding of ODQ is competitive with NO.